Dapsone (DDS), acedapsone (DADDS), solopsone and clofazimine
Dapsone, acedapsone, solopsone and clofazimine medicaments
HSN 3004 90 55 (Dapsone, acedapsone (DADDS), solopsone and clofazimine) is subject to Central Drugs Standard Control Organisation (CDSCO) drug registration and import licensing under the Drugs and Cosmetics Act, 1940. The Directorate General of Foreign Trade (DGFT) classifies this tariff line under the Restricted-import policy, and five mandatory documents must be uploaded in e-Sanchit before customs out-of-charge is granted.
- Registration certificate from CDSCO
- Import licence for drugs from CDSCO
- Batch release certificate from CDSCO
Procedural directions for customs clearance are issued by: Directorate General of Foreign Trade.
- 1Obtain a valid drug registration certificate (document code 101dc1) and an import licence for drugs (document code 9111dc) from the Central Drugs Standard Control Organisation before shipment. Both documents must be current and cover the specific active pharmaceutical ingredient — dapsone, acedapsone, solopsone or clofazimine — named on the bill of entry.Drugs and Cosmetics Act, 1940 · document codes 101dc1 and 9111dc per CBIC e-Sanchit mandate
- 2Upload all five mandatory documents in e-Sanchit before filing the bill of entry: Certificate of Analysis — Drug (0010dc), Batch Release Certificate (0030dc), Label of Consignment (0110dc), Registration Certificate — Drugs (101dc1), and Import Licence for Drugs (9111dc). The proper officer is required to verify each document code before granting out-of-charge.CCR e-Sanchit mandate — document codes 0010dc, 0030dc, 0110dc, 101dc1, 9111dc
The single most common error on this tariff line is uploading the registration certificate and import licence without simultaneously uploading the Certificate of Analysis and Batch Release Certificate — all five document codes are treated as a mandatory bundle, and a missing batch-level document (0030dc or 0010dc) is grounds for detention even when the product-level registration is in order. Because the CCR also contains an oxytocin prohibition note applicable to adjacent CTIs, importers must ensure their bill of entry and e-Sanchit uploads reflect only the dapsone/clofazimine product family and do not inadvertently trigger that prohibition flag.